GSK Gears Up To Fight NICE On Benlysta Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.